digital currency white paper Top Related searches

Ai Kelan: Liu Yi, the actual controller, intends to transfer 5% of the company's shares by agreement, with a total transaction price of 82.44 million yuan. Liu Yi, the controlling shareholder and actual controller, signed a share transfer agreement with Guangdong Nanchuan Private Equity Fund Management Co., Ltd., and Liu Yi intends to transfer 4 million unrestricted shares of the company (accounting for 5% of the company's total share capital) to Nanchuan Private Equity through agreement transfer. The transfer price is 20.61 yuan per share, and the total transaction price is 82.44 million yuan. This change in equity will not lead to changes in the controlling shareholder or actual controller of the company, and will not lead to changes in the control rights of listed companies.Botuo Bio: Adjust the profit distribution plan for the first three quarters of 2024. Botuo Bio announced that the total amount of cash dividends to be distributed in the company's profit distribution for the first three quarters of 2024 was adjusted from RMB 52.2583 million to RMB 53.2083 million. Before the adjustment, the company's total share capital was 105 million shares after deducting the shares in the company's repurchase special securities account, and a total cash dividend of 52.2583 million yuan was planned to be distributed. After adjustment, the company's total share capital is 107 million shares, of which 250,000 shares are repurchased in the special securities account, and the total number of shares actually participating in the profit distribution of the company is 106 million shares, with a total cash dividend of 53,208,300 yuan.People's Insurance Company of China: In the first November, the original insurance premium income of the three subsidiaries totaled 646.933 billion yuan. From January 1, 2024 to November 30, 2024, the original insurance premium income obtained through the subsidiaries of China People's Property Insurance Co., Ltd., China People's Life Insurance Co., Ltd. and China People's Health Insurance Co., Ltd. was 496.845 billion yuan, 102.591 billion yuan and 47.497 billion yuan respectively.

The Nikkei 225 index just broke through the 39,900.00 mark, and the latest report was 39,899.07, up 1.34% in the day.Ali's Taotian Supply Chain Company increased its capital to 50 million yuan, an increase of 400%. Tianyancha App shows that recently, Hangzhou Taotian Supply Chain Co., Ltd. has undergone industrial and commercial changes, and its registered capital has increased from 10 million yuan to 50 million yuan, an increase of 400%. At the same time, some key personnel have changed. Hangzhou Taotian Supply Chain Co., Ltd. was established in January 2016, and its legal representative is Zhang Bowen. Its business scope includes supply chain management services, professional design services, socio-economic consulting services, primary processing of edible agricultural products, primary processing of non-edible agricultural products, wholesale of aquatic products, acquisition of aquatic products, frozen processing of aquatic products, etc. It is wholly owned by Alibaba (China) Network Technology Co., Ltd.Russian Savings Bank: The contribution of artificial intelligence to Russia's GDP may reach 11.2 trillion rubles by 2030. Alexander Bedia Xin, the first vice chairman of the board of directors of Russian Savings Bank, said in his speech at the AI Journey that the application of artificial intelligence in Russia may bring 11.2 trillion rubles to GDP by 2030.

The OpenAI webpage shows that API, ChatGPT and Sora are all running normally.Italy's seasonally adjusted unemployment rate in the third quarter was 6.1%, and the previous value was 6.80%.The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)